Idorsia Ltd (SWX:IDIA)
6.12
-0.09 (-1.45%)
Jul 31, 2026, 5:30 PM CET
Idorsia Revenue
Idorsia had revenue of 52.86M CHF in the quarter ending June 30, 2026, a decrease of -26.83%. This brings the company's revenue in the last twelve months to 199.71M, down -8.06% year-over-year. In the year 2025, Idorsia had annual revenue of 220.58M with 96.06% growth.
Revenue (ttm)
199.71M
Revenue Growth
-8.06%
P/S Ratio
8.05
Revenue / Employee
437.97K
Employees
487
Market Cap
1.61B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.58M | 108.08M | 96.06% |
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Basilea Pharmaceutica AG | 232.38M |
| Santhera Pharmaceuticals Holding AG | 77.19M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Molecular Partners AG | 681.00K |
| MindMaze Therapeutics Holding | 642.00K |
| Xlife Sciences AG | 275.31K |
Idorsia News
- 3 days ago - Idorsia Earnings Call Transcript: Q2 2026 - Transcripts
- 3 days ago - Idorsia Quarterly report: Q2 2026 - Filings
- 3 days ago - Idorsia Earnings release: Q2 2026 - Filings
- 3 days ago - Idorsia Slides: Q2 2026 - Filings
- 6 days ago - Idorsia Signs QUVIVIQ Commercialization Deal With Jamjoom Pharma In Saudi, Levant; Stock Up - Nasdaq
- 5 weeks ago - Idorsia price target raised to CHF 4.50 from CHF 4 at Deutsche Bank - TheFly
- 7 weeks ago - Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon - GlobeNewsWire
- 2 months ago - Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology - GlobeNewsWire